慢性移植物抗宿主病一线治疗的真实世界研究
该单中心回顾性研究纳入243例cGVHD患者,评估以糖皮质激素为基础的一线治疗。6个月客观缓解率为60.0%,无失败生存率为73.6%,不同器官反应异质,肝脏受累提示预后不良。
要点
- cGVHD一线治疗6个月ORR为60.0%,FFS率为73.6%
- 皮肤和关节/筋膜反应较好,肺受累反应率最低(30.0%)
- 肝脏受累是治疗有效的独立危险因素(OR=0.506,P=0.021)
核心结论
- 以糖皮质激素为基础的一线治疗在cGVHD中疗效可接受,并能改善部分患者症状负荷。
- 不同器官治疗反应存在显著异质性,肝脏受累提示预后不良。
研究设计与样本
- 单中心回顾性真实世界研究,纳入2017年1月至2023年12月陆军军医大学第二附属医院确诊cGVHD并接受一线治疗的243例患者。
- 159例(65.4%)接受标准方案(激素联合/不联合钙调磷酸酶抑制剂),51例(21.0%)接受激素联合二线药物(芦可替尼或西罗莫司),33例(13.6%)因禁忌证未用激素(单用芦可替尼)。
主要发现
- 治疗6个月时132例达完全或部分缓解,ORR为60.0%,FFS率为73.6%。
- 皮肤和关节/筋膜ORR分别为66.4%和68.2%,肺受累ORR最低为30.0%。
- 中位随访43.9个月,5年总生存率为80.0%,5年NRM为7.5%。
- 治疗有效组5年总生存率显著高于无效组(89.3%对75.4%,P<0.01),5年NRM显著低于无效组(3.6%对12.6%,P=0.01)。
- 治疗有效组LSS症状负荷显著低于无效组[(7.3±5.6)分对(12.3±7.8)分,P=0.01],SF-36和EQ-5D-5L组间差异无统计学意义。
关键数值与推荐
- 多因素分析显示肝脏受累是一线治疗有效的独立危险因素(OR=0.506,P=0.021)。
临床怎么用
- cGVHD一线治疗可优先考虑以糖皮质激素为基础的方案,但需关注器官特异性反应差异。
- 肝脏受累患者一线治疗反应可能较差,需密切监测并考虑早期调整策略。
局限性
- 本研究为单中心回顾性真实世界研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To systematically evaluate the efficacy, safety, quality of life, and related influencing factors of first-line treatment in patients with chronic graft-versus-host disease (cGVHD) and to provide evidence-based support for optimizing treatment strategies. Methods: This single-center retrospective analysis involved 243 patients diagnosed as having cGVHD who received first-line treatment at the Second Affiliated Hospital of Army Medical University between January 2017 and December 2023. Of the patients, 159 (65.4% ) received the standard regimen (corticosteroids with or without calcineurin inhibitors), 51 (21.0% ) received corticosteroids plus a second-line agent (ruxolitinib or sirolimus), and 33 (13.6% ) did not receive corticosteroids as first-line therapy due to contraindications (ruxolitinib alone). The primary endpoints were the overall response rate (ORR) and failure-free survival (FFS) at 6 months after treatment. The secondary endpoints comprised organ-specific responses, survival rates, nonrelapse mortality (NRM), recurrence rates, and quality of life [assessed using the Lee Symptom Scale (LSS), the 36-Item Short Form Health Survey (SF-36), and the EuroQol 5-Dimension 5-Level instrument (EQ-5D-5L) ]. Results: At 6 months after treatment, 132 patients achieved complete or partial response to first-line therapy, yielding an ORR of 60% and an FFS of 73.6%. ORRs were higher in the joint/fascia (68.2% ) and the skin (66.4% ) and the lowest in the lungs (30.0% ). The median follow-up was 43.9 months, the 5-year overall survival rate was 80.0%, and the 5-year NRM was 7.5%. Both overall survival and nonrelapse mortality were significantly better in responders than in nonresponders (P<0.01 and P=0.01, respectively). Multivariate analysis identified liver involvement as an independent risk factor for adverse treatment reactions (OR=0.506, P=0.021). Quality-of-life surveys indicated that the symptom burden was significantly lower in responders than in nonresponders (7.3±5.6 vs 12.3±7.8, P=0.01), whereas no significant between-group differences were observed in SF-36 physical and mental component scores or the EQ-5D-5L utility index. Conclusion: Glucocorticoid-based first-line treatment showed acceptable efficacy and reduced symptom burden in some patients with cGVHD. However, significant heterogeneity was observed in treatment responses among different organs, and liver involvement indicated poor prognosis. 目的: 系统评估慢性移植物抗宿主病(cGVHD)患者接受以糖皮质激素为基础的一线治疗的疗效、安全性、生活质量及相关影响因素,为优化治疗策略提供循证依据。 方法: 本研究为单中心回顾性真实世界研究,纳入2017年1月至2023年12月在陆军军医大学第二附属医院确诊cGVHD并接受一线治疗的243例患者。159例(65.4%)患者接受标准方案(激素联合/不联合钙调磷酸酶抑制剂),51例(21.0%)患者接受激素联合二线药物治疗方案(激素联合芦可替尼或西罗莫司),33例(13.6%)患者因禁忌证一线治疗未使用激素(单用芦可替尼)。主要终点为治疗6个月后的客观缓解率(ORR)和无失败生存(FFS)率,次要终点包括器官特异性反应、生存率、非复发死亡率(NRM)、复发率及生活质量[采用Lee症状学量表(LSS)、医学结局研究36项简短健康调查量表(SF-36)、五水平五维健康量表(EQ-5D-5L)评估]。 结果: 6个月时132例患者一线治疗达完全或部分缓解,ORR为60.0%,FFS率为73.6%。皮肤、关节/筋膜等器官反应较好(ORR分别为66.4%、68.2%),肺受累反应率最低(30.0%)。中位随访43.9个月,5年总生存率为80.0%,治疗有效组显著高于治疗无效组(89.3%对75.4%,P<0.01);5年NRM为7.5%,治疗有效组显著低于治疗无效组(3.6%对12.6%,P=0.01)。多因素分析显示肝脏受累是一线治疗有效的危险因素(OR=0.506,P=0.021)。生活质量调查显示,治疗有效组LSS症状负荷显著低于无效组[(7.3±5.6)分对(12.3±7.8)分,P=0.01],而SF-36躯体健康总评、精神健康总评及EQ-5D-5L量表效用指数差异无统计学意义。 结论: 以糖皮质激素为基础的一线治疗在cGVHD患者中显示出可接受的疗效并可以改善部分患者症状负荷,不同器官反应存在显著异质性,肝脏受累提示预后不良。.
引用
- Dong XQ, He YD, Huang SQ, et al. [First-line treatment for chronic graft-versus-host disease: a real-world study]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161657. doi:10.3760/cma.j.cn121090-20250923-00435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。